Category Archives: Insulin Delivery

Novo Nordisk Expands Research Collaboration for Oral Drug Delivery Technologies; eGenesis and University of Miami Collaboration for Human-Compatible Islet Cells

Two cardiometabolic-related news items have been observed: Novo Nordisk announced it will be expanding its existing research collaboration for oral drug delivery technologies with MIT and Brigham and Women’s Hospital; and eGenesis announced a research collaboration with the University of Miami Leonard M. Miller School of Medicine to evaluate gene-edited pancreatic human-compatible islet cells in T1DM. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

BD Spinoff Embecta Hosts Virtual Investor Event; Discloses Insulin Patch Pump Program for T2DM

Embecta hosted a virtual investor event (slides; webcast) where management provided an overview of the company in terms of the global diabetes landscape, its position in the market, benefits of the spin-off, and global growth opportunities. Recall, in May 2021, BD announced plans to spin off its diabetes business as an independent, publicly-traded company (previous FENIX insight) and in February 2022, the company’s board of directors approved the planned spinoff (view press release). Of note, during the investor event, Embecta disclosed that the company is developing an insulin patch pump designed to reduce adoption barriers for individuals with T2DM. Below, FENIX provides highlights and insights from the presentation as it relates to the patch pump device.

This content is for Read Less members only.
Register
Already a member? Log in here

Beta Bionics Management Changes Ahead of Insulin-only iLet Bionic Pancreas Launch; Glooko Partners with Johns Hopkins

Two cardiometabolic-related news items have been observed: Beta Bionics recently announced executive leadership and board transitions ahead of launching its insulin-only iLet bionic pancreas; and Glooko announced a collaboration with Johns Hopkins HealthCare Solutions to helps patients with their diabetes management. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Insulet FY ’21 Earnings Update; Novo Partners with Vonage for IO Customer Support; Esperion, Teladoc, and Adocia Q4 ‘21 Earnings Updates

A series of cardiometabolic-related news items have been observed: Insulet hosted its FY ’21 earnings call (press release); Vonage recently announced Novo Nordisk has chosen Vonage Contact Center (VCC) to support Novo’s international operations customer engagement; Esperion (press release; slides) and Teladoc (press release; slides) hosted their respective Q4 ‘21 earnings calls; and Adocia published its Q4 ’21 and FY ‘21 earnings. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Provention Bio Refiles Teplizumab BLA; Medtronic and Tandem Q4 ’21 and FY ’21 Earnings Updates; Lilly Invests $700M in New Lilly Institute for Genetic Medicine; RosVivo Therapeutics and Lilly Sign MTA for RSVI-301; February 21-24 CHMP Agenda

A series of cardiometabolic-related news items have recently been observed from Provention Bio, Medtronic, Tandem, Lilly, RosVivo Therapeutics, and the CHMP. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Insulet Partners with Nintendo’s Animal Crossing Game; Beta Bionics Raises $57M in Series C Financing

Two cardiometabolic-related news items have been observed: Insulet announced it will be partnering with Nintendo for integration into the Animal Crossing: New Horizons game; and Beta Bionics announced the closing of its $57M Series C. Below, FENIX provides highlights and insights for the respective new items, including thoughts on how Insulet is likely using Animal Crossing to source new Omnipod 5 patients.

This content is for Read Less members only.
Register
Already a member? Log in here

Tandem’s Mobile Bolus Feature Cleared by FDA

Tandem announced FDA has cleared its remote bolus insulin dosing feature for its t:connect mobile app. The updated t:connect mobile app provides t:slim X2 insulin pump users the ability to program/cancel bolus insulin requests through their compatible iOS or Android smartphone. Below, FENIX provides brief thoughts on what the launch of the remote bolus feature means for Tandem, Insulet, and Medtronic.

This content is for Read Less members only.
Register
Already a member? Log in here

Dexcom Q4 ‘21 and FY ‘21 Earnings Update

Dexcom hosted its Q4 ’21 earnings call (press release; slides) and provided updates to its clinical and commercial activities, including the anticipated G7 OUS and US launches throughout 2022. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo Q4 ’21 London Earnings; Sanofi and Regeneron Q4 ‘21 and FY ‘21 Earnings Updates

A series of cardiometabolic-related news items have been observed: Novo Nordisk hosted its post-Q4 ’21 earnings event (see previous FENIX insight on Q4 ’21 Novo earnings from February 2); and Sanofi (press release; slides; view infographic) and Regeneron (press release; slides), hosted their respective Q4 and FY ’21 earnings calls. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here